GRAIL
GRAL | NASDAQ
$105.60
-$10.29 (-8.88%)
At close: Nov 16, 2026, 4:00 PM ET
$106.90
+$1.30 (+1.23%)
After-hours:
Nov 16, 2026, 7:51 PM ET
GRAIL Company Profile
Company profile explainedCompany Profile
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Key Executives
| Name | Position |
|---|---|
| Joshua J. Ofman | Chief Executive Officer & Director |
| Abram Barth | Chief Legal Officer & Corporate Secretary |
| Alison Highlander | Chief People Officer |
| Satnam Alag | Chief Technology Officer |
| Aaron Freidin | CFO & Head of Corporate Development |
| Andrew John Partridge | Chief Growth Officer |
| Paul Ciccolella | Senior Vice President of Global Development & Operations |
| Robert Ragusa | Advisor |
| Sir Harpal S. Kumar | Chief Scientific Officer and President of Global Clinical & Medical Affairs |
| Trish Rowland | Senior Vice President of Corporate Communications |
GRAIL
| Country | United States |
| IPO Date | Jun 12, 2024 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 910 |
| CEO | Joshua J. Ofman |
Contact Details
1525 O’Brien Drive Menlo Park,
California 94025 United States
Stock Details
| Ticker Symbol | GRAL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001699031 |
| CUSIP Number | 384747101 |
| ISIN Number | US3847471014 |
| SIC Code | 8071 |
Recent News
- 6 days ago / seekingalpha.comGRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript
- 7 days ago / 247wallst.comHer Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029
- 12 days ago / zacks.comGRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
- 12 days ago / seekingalpha.comGRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comWhat GRAIL (GRAL) Said on Its Q3 Earnings Call
- 12 days ago / prnewswire.comGRAIL Reports Third Quarter 2026 Financial Results
- 19 days ago / zacks.comGRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
- 20 days ago / prnewswire.comGRAIL to Present at the UBS Global Healthcare Conference
- 26 days ago / prnewswire.comGRAIL to Announce Third Quarter 2026 Financial Results
- 1 month ago / wsj.comFirst-Class Amenity Kits Have Become Holy Grail Collectibles
Add to Watchlist
Select watchlists to add or remove GRAL